Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ NIV/IMV/death 64% Improvement Relative Risk Sanson et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Prospective study of 69 patients in Italy (March - September 2020) Lower progression with higher vitamin D levels (p=0.031) Sanson et al., Irish J. Medical Science, doi:10.1007/s11845-022-02952-9 Favors vitamin D Favors control
A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients
Sanson et al., Irish Journal of Medical Science (1971 -), doi:10.1007/s11845-022-02952-9
Sanson et al., A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in.., Irish Journal of Medical Science (1971 -), doi:10.1007/s11845-022-02952-9
Feb 2022   Source   PDF  
  All Studies   Meta
Prospective study of 69 hospitalized COVID-19 pneumonia patients, showing higher risk of combined NIV/IMV/60-day death with low vitamin D levels. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
NIV/IMV/death, 64.0% lower, RR 0.36, p = 0.03, high D levels (≥30ng/mL) 2 of 9 (22.2%), low D levels (<30ng/mL) 37 of 60 (61.7%), NNT 2.5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sanson et al., 19 Feb 2022, prospective, Italy, peer-reviewed, 13 authors, study period March 2020 - September 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Irish Journal of Medical Science (1971 -) ORIGINAL ARTICLE A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID‑19 patients Gianfranco Sanson1 · Amedeo De Nicolò2 · Verena Zerbato3 · Ludovica Segat4 · Raffaella Koncan4 Stefano Di Bella1,3,8 · Jessica Cusato2 · Alessandra di Masi5 · Andrea Palermo6 · Pietro Caironi7 · Pierlanfranco D’Agaro4 · Roberto Luzzati1,3 · Antonio D’Avolio2 · Received: 28 August 2021 / Accepted: 8 February 2022 © The Author(s) 2022 Abstract Purpose We aimed to assess the combined role of vitamin D and albumin serum levels as predictors of COVID-19 disease progression. Methods We conducted a prospective observational study on adult patients hospitalized for SARS-CoV-2 pneumonia (March–September 2020). Vitamin D and albumin serum levels were measured on admission. These variables were categorized in albumin < 3.5 or ≥ 3.5 g/dL and vitamin D < 30 ng/mL or ≥ 30 ng/mL. We excluded patients with known bone diseases, renal failure, hypercalcemia and/or treated with antiepileptic drugs and steroids, and patients who received previous vitamin D supplementation. A composite outcome including any ventilatory support, P ­ aO2/FiO2 ratio, and 60-day mortality was defined. Results Sixty-nine patients were enrolled, of whom 50% received non-invasive (NIV) or invasive mechanical ventilation (IMV), 10% died, whereas 89% and 66% presented low albumin and low vitamin D serum levels, respectively. No correlation between vitamin D and albumin levels was found. In multivariable logistic regression analyses adjusted for sex and age-corrected comorbidities, patients having albumin < 3.5 g/dL and vitamin D < 30 ng/mL showed a significant increased risk for all study outcomes, namely NIV/IMV (OR 3.815; 95% CI 1.122–12.966; p = 0.032), NIV/IMV or death (OR 3.173; 95% CI 1.002–10.043; p = 0.049) and ­PaO2/FIO2 ≤ 100 (OR 3.410; 95% CI 1.138–10.219; p = 0.029). Conclusion The measurement of both vitamin D and serum albumin levels on COVID-19 patients’ admission, and their combined evaluation, provides a simple prognostic tool that could be employed to guide prompt clinical decisions. Keywords COVID-19 · Human serum albumin · SARS-CoV-2 · Vitamin D
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop